Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3

NCT01235013 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: Maraviroc

Sponsor

Hospital Clinic of Barcelona